About the Company
Adverum Biotechnologies, Inc., formerly known as Avalanche Biotechnologies, is a publicly traded clinical stage gene therapy company located in Redwood City, California. The company is targeting unmet medical needs for serious ocular and rare diseases, including wet age-related macular degeneration (wet AMD).
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Adverum Biotechnologies, Inc.
Bullish insiders at Adverum Biotechnologies, Inc. (NASDAQ:ADVM) loaded ...
Based on our data, Adverum Biotechnologies insiders have about 1.9% of the stock, worth approximately US$4.0m. We prefer to see high levels of insider ownership.
Adverum Biotechnologies Reports Second Quarter 2025 Financial Results and Provides Pipeline Highlights
ARTEMIS Phase 3 trial enrollment exceeding expectations; driven by strong retina specialist and patient enthusiasm for a potential One And Done™ therapy for wet AMD - ARTEMIS enrollment completion ...
Adverum Biotechnologies to Host Webcast to Review Clinical Data from ...
REDWOOD CITY, Calif., July 10, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for ...
ADVM - Adverum Biotechnologies Inc News | Morningstar
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Adverum Biotechnologies, Inc. - ADVM GlobeNewswire Apr 25, 2025 10:12am ...
ADVM | Adverum Biotechnologies Inc. Profile | MarketWatch
Adverum Biotechnologies Inc. 100 Cardinal Way Redwood City, California 94063 Phone1 650 656-9323 IndustryBiotechnology SectorHealth Care/Life Sciences Fiscal Year-end12/2025 Revenue$1M Net Income ...
Adverum Biotechnologies, Inc.: Adverum Biotechnologies Reports Fourth ...
REDWOOD CITY, Calif., April 15, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy to preserve sight for life in highly ...
Adverum Biotechnologies to Participate in the Oppenheimer 35th Annual ...
REDWOOD CITY, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for ...
Adverum Biotechnologies Appoints C. David Nicholson, Ph.D. to its Board ...
REDWOOD CITY, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly ...
Why Adverum Biotechnologies Stock Is Imploding Today
Adverum Biotechnologies' stock was down by 60.2% as of 11:30 a.m. EDT. So what ADVM-022 is an experimental gene therapy for the treatment of diabetic macular edema (DME).
Adverum Biotechnologies Announces First Subject Dosed with Ixo-vec in ...
Adverum Biotechnologies, Inc. T: 650-649-1358 E: areddi@adverum.com Media Megan Talon Associate Director, Corporate Communications Adverum Biotechnologies, Inc. T: 650-649-1006 E: mtalon@adverum.com ...
Adverum Biotechnologies Appoints Mike Fitzgerald as Vice President ...
MENLO PARK, Calif., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ophthalmology and rare ...
AVU0 | Adverum Biotechnologies Inc. Profile | MarketWatch
Adverum Biotechnologies Inc. 100 Cardinal Way Redwood City, California 94063 Phone1 650 656-9323 IndustryBiotechnology SectorHealth Care/Life Sciences Fiscal Year-end12/2025 Revenue€1M Net ...
Similar Companies
Loading the latest forecasts...